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Studiesonligandbindingpotentialofglycyrrhizicacid,apotentialagonisttoPPARγ,displayedencouragingresultsinamelioration
of metabolic syndrome. The regulation of gene cassettes by PPARγ aﬀects glucose homeostasis, lipid, lipoprotein metabolism and
adipogenesis. This study was performed to determine the eﬀects of GA on total PPARγ and LPL expression levels, lipid parameters
and HOMA-IR. Oral administration of 100mg/kg GA for 24 hours resulted in an increase in insulin sensitivity with decreases
in blood glucose, serum insulin and HOMA-IR. Improvement in serum lipid parameters was also observed with a decrease in
triacylglycerol, total cholesterol and LDL-cholesterol and an elevation in HDL-cholesterol. GA administration also resulted in up-
regulation of total PPARγ and LPL expression levels in the visceral and subcutaneous adipose tissues, abdominal and quadriceps
femoris muscles, as well as liver and kidney, with a signiﬁcant up-regulation only in the visceral adipose tissue, abdominal and
quadricepsfemorismuscles.Thus,oraladministrationof100mg/kgGAfor24hoursimprovedinsulinsensitivityandlipidproﬁles
and induced upregulation of total PPARγ and LPL expression levels in all studied tissues.
1.Introduction
Metabolic syndrome, or more commonly known as syn-
drome X, encompasses a constellation of risk factors such as
visceral (abdominal or central variant) obesity, insulin resis-
tance (IR), glucose intolerance, dyslipidaemia and hyper-
tension [1]. Studies have shown that obesity and insulin
resistance are the two predominant underlying mechanisms
for the development of metabolic syndrome [2]. Insulin
resistance is also a characteristic in most patients with type
2d i a b e t e sm e l l i t u s( T 2 D M )[ 2].
T2DM involves the impairment of insulin action and
secretionfromthepancreaticβ-cells.Bothfactorswillcollec-
t i v e l yi n c r e a s eb l o o dg l u c o s el e v e l s[ 3]. Research has proven
that impaired insulin secretion together with peripheral
insulin resistance is the main regulator behind the incidence
of T2DM [4].
Peroxisome proliferator-activated receptor gamma
(PPARγ) gene is a well known susceptibility gene for
T2DM due to the presence of polymorphisms within the
gene. PPARγ is a ligand-activated transcription factor
originating from the nuclear hormone receptor superfamily
[5]. PPARs form heterodimers with retinoid X receptors
(RXRs) and bind to the hexanucleotidic PPAR responsive
element (PPRE), thereby regulating the expression of
target genes involved in lipid and carbohydrate metabolism
[6].
Since PPARγ is a major regulatory transcription factor, it
is involved in the regulation of several biochemical pathways
through the transcriptional control of target genes [7].
Among the pathways involved through the regulation of
gene cassettes by PPARγ are glucose homeostasis, lipid
and lipoprotein metabolism, inﬂammatory and immune
r e s p o n s e sa sw e l la sa d i p o g e n e s i s[ 8].2 PPAR Research
PPARγ is the master regulator of fat cell function that
governs diﬀerentiation of pre-adipocyte precursor cells into
mature adipocytes capable of lipid ﬁlling as well as the
mediation of hormone and cytokine expression [9]. In
addition to an increase in smaller and more insulin sensitive
adipocytes, PPARγ activation also promotes apoptosis of
mature, lipid-ﬁlled visceral adipocytes and a redistribution
of the free fatty acids towards the subcutaneous adipose
tissues [5]. The increase in adipocyte number increases
the lipid storage capacity and indirectly confers protection
towards non-adipose tissues in the event of excessive lipid
accumulation [10].
Lipoprotein lipase (LPL), a water-soluble enzyme, liber-
ates free fatty acids through the hydrolysis of ester bonds
of water-soluble substrates such as TAG, phospholipids
and cholesterol esters [11]. LPL is synthesized and highly
expressed in the adipose tissues, cardiac and skeletal muscle,
kidney, and mammary glands while lower levels are present
in the liver, adrenal and brain [12]. The expression of LPL
is governed by the activation of PPARγ by cognate ligands
as LPL is a downstream gene of PPARγ. The PPARγ/RXR
complex would bind to the PPRE present in the promoter
region of theLPLgeneand increases theLPLgeneexpression
[13]. The induction of lipoprotein lipase synthesis by PPARγ
is mainly in the mature adipocytes in order to increase local
generation of free fatty acids [14].
It has been reported that Glycyrrhizic acid (Glycyrrhizin
or Glygyrrhizinate, GA), the bioactive compound extracted
from roots of licorice plants, has anti-diabetic properties
[15]. In view of the above, the present study was undertaken
to investigate the eﬀects of orally-administered GA on
total PPARγ and LPL expression levels and HOMA-IR
in rats.
2.MaterialsandMethods
2.1. Animals Studies. Male Sprague Dawley rats (Rattus
norvegicus) (6 weeks old) obtained from University Malaya’s
Animal House (University Malaya, Malaysia) were housed
1 per cage with free access to food and drinking water.
They were maintained on a 12-hour light-dark cycle in a
room with controlled temperature (24 ± 1◦C) and humidity
(55 ± 10%). The use and handling procedure of animals
had been approved by the Monash University Animal
Ethics Committee according to the 2004 NHMRC Australian
Code of Practice for the Care and Use of Animal for
Scientiﬁc Purposes and Relevant Victorian Legislation
(Prevention of Cruelty to Animals Act 1986) (AEC:
SOBSB/MY/2006/46).
2.2. In-Vivo Assay. The rats were divided into 2 groups
(control and treated) [8 rats per group]. The treated group
wasgiven100mgkg−1 ofGA(SigmaChemicalCo.,St.Louis,
MO,USA)orallywhilethe controlgroupwasgiventapwater
without GA. The rats were fed ad libitum with Glenn Forest
stock-feeder rat chow during the treatment period of 24
hours. Upon completion of the projected treatment period,
the rats fasted for 12 hours prior to humane sacriﬁce under
the inﬂuence of anaesthesia via intraperitoneal administra-
tion of pentobarbital sodium (120mg/kg, IP).
Blood was withdrawn from the apex of the heart for
measurement of glucose and insulin levels. Tissues (subcu-
taneous and visceral adipose tissues, abdominal and quadri-
ceps femoris muscles, and liver and kidney) were harvested
for measurement of total PPARγ and LPL expression levels.
2.3.LaboratoryAssay. Bloodglucosewasanalyzedbyglucose
oxidase method employing a Powerwave XS Microplate
Scanning Spectophotometer (BIO-TEK, USA). Enzyme
immunoassay (LINCO-Millipore Corp., US) was used to
measure serum insulin. For the estimation of insulin sensi-
tivity,thehomeostasismodelassessmentofinsulinresistance
(HOMA-IR) was calculated (concentration of glucose ×
concentration of insulin/22.5) [16].
Total cholesterol and TAG were measured with a Randox
CH200 Cholesterol kit (Randox, UK) and a Wako Triglyc-
eride E kit (Wako, Japan). To determine the level of HDL-
cholesterol, HDL-cholesterol was ﬁrst separated from the
LDL and VLDL fractions by precipitation of the latter two
using the Randox CH203 HDL precipitant, followed by a
cholesterol assay using the Randox CH200 Cholesterol kit.
The levels of total cholesterol, TAG and HDL cholesterol
obtained were used to calculate LDL-cholesterol using the
Friedewald formula [17].
2.4. Real-Time Reverse Transcription Polymerase Chain Reac-
tion (RT-PCR) Quantiﬁcation of Total PPARγ and LPL
Expression
2.4.1.RNAIsolationandRT-PCR. TotalmRNAwasobtained
from subcutaneous and visceral adipose tissues, abdominal
and quadriceps femoris muscles, and liver and kidney of
each animal using Qiagen RNeasy Mini Kit and Qiagen
RNeasy Lipid Tissue Mini Kit according to the protocol
provided by the manufacturer. The concentration of the
mRNA was determined by measuring the absorbance at 260
and 280nm. The quality of the mRNA was conﬁrmed by
ethidium bromide staining of 18S and 28S ribosomal RNA
after electrophoresis on 1.2% agarose gel. 1μgo ft o t a lR N A
was reverse-transcribed with Qiagen Omniscript reverse
transcriptase (Qiagen, USA). The expression of total PPARγ
andLPLwasassessedbyquantitativeRT-PCR,usingOpticon
Monitor 3 (MJ Research Inc, UK) with Locked Nucleic
Acid (LNA) Dual-labeled Fluorogenic Probes detection. The
forward and reverse primers for the ampliﬁcations of total
PPARγ and LPL expression levels are listed in Table 1.
The comparison of total PPARγ and LPL expression levels
between control and treated rats was performed using the
Comparative Ct (ΔΔCt) Method, with BAC as reference,
treated group as target and control group as calibrator.
2.5. Statistical Analysis. Data were expressed as mean ±
standard error of mean. Statistical analyses of total PPARγ
and LPL expression levels were performed using the Relative
Expression Software Tool (REST c ) MCS Beta 2006 whilePPAR Research 3
Table 1: Primer sequences used for real-time PCR.
Genes Primers
Total
PPARγ
Forward 5 -CCCTGGCAAAGCATTTGTAT-3 
Reverse 5 -GGTGATTTGTCTGTTGTCTTTCC-3 
LPL
Forward 5 -CAGCAAGGCATACAGGTG-3 
Reverse 5 -CGAGTCTTCAGGTACATCTTAC-3 
β-actin
(BAC)
Forward 5 -CAGCAAGGCATACAGGTG-3 
Reverse 5 -CGAGTCTTCAGGTACATCTTAC-3 
that of all other parameters was performed using the Statisti-
cal Package for the Social Sciences (SPSS) version 16.0 (SPSS
Inc., Chicago, IL, USA). A P value of ≤.05 was considered
signiﬁcant.
3. Results
3.1. Biochemical Analysis. Rats administered with GA
showed 65% (control, 9.31 ± 0.40mmol/L; treated, 3.26 ±
0.23mmol/L) and 37% (control, 2.71 ± 0.41ng/mL; treated,
1.53 ± 0.12ng/mL) decrease in blood glucose (P<. 05) and
serum insulin (P>. 05) levels, respectively, compared to
the control rats (Figure 1). Insulin resistance, calculated as
HOMA-IR, was 83% (control, 1.38 ± 0.12; treated, 0.62 ±
0.05) lower in the GA-administered rats compared to the
control ones (Figure 1)( P<. 05).
Consistent improvement in all lipid parameters was
observed in the GA-administered rats relative to the control
(Figure 2). Mean serum TAG, total cholesterol and LDL-
cholesterol showed a 28.72%, 21.55%, and 28.60% reduc-
tion, respectively, (control, 1.22 ± 0.14mmol/L; treated,
0.87 ± 0.10mmol/L; control, 2.04 ± 0.13mmol/L; treated,
1.60 ± 0.11mmol/L; control, 0.77 ± 0.08mmol/L; treated,
0.54 ± 0.05mmol/L, resp.) (P>. 05). Rats administered
with GA showed an elevation in HDL-cholesterol by 17.95%
compared to control rats (control, 1.08 ± 0.10mmol/L;
treated, 1.32 ±0.06mmol/L) (P>. 05).
3.2. Total PPARγ and LPL Expression in Rat Tissues. Abdom-
inal muscle (MA) displayed the highest fold diﬀerence
expression of total PPARγ followed by quadriceps femoris
(MT), visceral adipose tissue (ATV), subcutaneous adipose
tissue (ATS), liver (L), and kidney (K) (Figure 3). Compared
with the control groups, relative expression of total PPARγ
in GA-administered rats was higher in all tissues. The MA,
MT and ATV displayed a signiﬁcant increased fold diﬀerence
(P<. 05)of15.16±5.58fold,13.09±3.11foldand8.85±3.62
fold, respectively, when compared to the control group. The
ATS,LandKalsodisplayedincreasedfolddiﬀerenceof2.00±
0.81 fold, 5.07 ± 2.17 fold and 2.26 ± 1.08 fold, respectively,
albeit an insigniﬁcant increase (P>. 05).
The increased LPL expression in all studied tissues
(Figure 3)wassimilartotheexpressionofPPARγ namelythe
MA,MT,andATValsodisplayedasigniﬁcantincreaseinfold
diﬀerence (P<. 05) and of 11.02±4.06 fold, 8.82±3.01 fold,
and 4.53 ± 2.66 fold, respectively. A similar trend of non-
signiﬁcant increase (P>. 05) in fold diﬀerence was observed
in the ATS (1.27 ± 0.85 fold), L (2.76 ± 1.97 fold) and K
(2.18 ± 1.44 fold).
4. Discussion
The present study showed signiﬁcant decrease in blood
glucose and HOMA-IR in rats administered with 100mg/kg
o fG Af o r2 4h o u r s .T a k i ie ta l .[ 18] and Nakagawa et al.
[19] reported that normal and obese genetically diabetic KK-
Ay mice given ethanolic extract of licorice roots displayed
suppression of blood glucose levels. Activation of PPARγ
was shown to cause a decrease in blood glucose levels
through the inhibition of glucagon gene transcription and
secretion by inhibiting the transcriptional activity of PAX6
[20].
The decrease in the serum insulin levels could be
attributed to the insulin sensitization properties bestowed
upon the activation of PPARγ. Under a normoglycaemic
state, circulatory insulin would oversee the suppression of
hepatic glucose production and enhancement of glucose
uptake by peripheral organs [5]. Insulin has also been
implicatedinthebiosynthesisofLPL[21],wheretheinsulin-
signaling pathway activates PPARγ, which subsequently
binds to the PPRE at the LPL gene promoter region to
upregulate LPL gene expression [22]. A signiﬁcant drop in
the serum insulin levels was found in diabetic KK-Ay mice
for 7 weeks fed with ethanolic extract of licorice roots [18].
Results from our study exhibited a similar trend but the drop
was non-signiﬁcant probably due to the shorter treatment
duration.
A decrease in HOMA-IR in the present study could be
due to the lowered insulin and glucose levels as HOMA-IR
reﬂects the product of glucose output and insulin secretion
[23]. Therefore, a lower HOMA-IR indicates improved
insulin sensitivity. Hanyu et al. [22] demonstrated that
plasma LPL activity reﬂects whole-body insulin sensitivity
and is negatively correlated with the HOMA-IR. The results
of this study were in agreement with Hanyu et al. [22]w h e r e
the higher insulin sensitivity (lower HOMA-IR) in the GA-
administered rats developed concomitantly with the increase
intissueLPLexpression.Inaddition,theactivationofPPARγ
also regulates the adipocyte hormone gene expression to
improveinsulinsensitivity.ActivationofPPARγ increasesthe
adiponectin expression which potentiates insulin sensitivity
in the liver and skeletal muscles [24].
Inthepresentstudy,increaseintissueLPLexpressionwas
consistent with the improvement of serum lipid parameters
intheGA-administeredrats.AreductioninserumTAG,total
c h o l e s t e r o la n dL D L - c h o l e s t e r o lt o g e t h e rw i t ha ne l e v a t i o n
in HDL-cholesterol was observed. The decrease in TAG in
GA-administered rats may be attributed to the action of GA
which causes an increase in its tissue uptake. Berthiaume
et al. [25] have demonstrated that inhibition of 11β-
hydroxysteroid dehydrogenase 1 (11β-HSD1) could reduce
hepaticverylowdensitylipoprotein(VLDL)whichmayhave
increased the hepatic free fatty acid oxidation. Thus, this
could have caused the reduction in TAG as it is required to
boost the VLDL secretion. The decrease in LDL-cholesterol4 PPAR Research
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Figure 1: (a) Blood glucose, (b) serum insulin, and (c) HOMA-IR levels in GA-administered rats (∗ indicates P<. 05).
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Figure 2: Serum lipid proﬁles in GA-administered rats.
in GA-administered rats may be due the lowering eﬀect
of VLDL since LDL is a derivative of VLDL. Elevation of
HDL-cholesterol in GA-administered rats may be due to the
increased apo A-I production since the rate of HDL synthesis
is dependent on the production of apo A-I [26].
With reference to Figure 3, increased LPL expression was
also seen in adipose tissue. LPL is a downstream gene that
is regulated by the activation of PPARγ, where an increase
in the expression of PPARγ w o u l dl e a dt oa ni n c r e a s ei n
the expression of LPL [27]. Thus, the increase in PPARγ
expression is accompanied by a similar signiﬁcant increase in
LPL gene expression. LPL is a key enzyme in the metabolism
of triglyceride-rich lipoproteins and plays the role of a gate-
keeperinenergymetabolismbycontrollingthegenerationof
fatty acids. In adipose tissue, the increase in LPL production
could enhance the clearance of plasma triglycerides and
provide the (pre-)adipocytes with additional fatty acids,
which can further stimulate the transactivation capacity of
PPAR [28]. The upregulation of PPARγ in adipose tissues
hadbeenshowntocauseanincreaseinglucosetransporter-1
(GLUT4) and c-Cbl associating protein (CAP), pivotal both
for the translocation of GLUT4 to the cell surface and for the
enhanced glucose uptake [5].
Although the liver is an organ involved in glucose and
lipid metabolism, only low levels of PPARγ were detected
in the liver [14]. Although the exact mechanism involved in
the activation of PPARγ in the liver remains unknown, it has
beenpostulatedthatacirculatingfactormightberesponsible
for the stimulation of hepatic total PPARγ transcription
during a state of increased energy availability [29]. The
upregulation of hepatic total PPARγ would in turn activate
several genes such as adipocyte fatty acid-binding protein
(aP2) and fatty acid translocase (FAT/CD36), previously
present only in trace amounts in the liver of lean mice.
Activation of aP2 in the liver prevents the detrimental eﬀects
of free fatty acids on cells and membranes while that of
FAT/CD36 facilitates fatty acid transport which ultimately
lowers serum triacylglycerol levels and improves insulin
sensitivity [30].
Muscles are pivotal tissues in glucose homeostasis as
it is the primary organ for the insulin-stimulated glucosePPAR Research 5
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Figure 3: Relative expression (fold diﬀerence) for (a) total PPARγ and (b) LPL in tissues with BAC as reference, GA-administered group
as target, and control group as calibrator. ATS: Subcutaneous adipose tissue, ATV: Visceral adipose tissue, MA: Abdominal muscle, MT:
Quadriceps femoris muscle, L: Liver, K: Kidney (∗ indicates P<. 05).
disposal. Signiﬁcant increases were observed in total PPARγ
and LPL expression levels. Higher fold diﬀerence expression
wasfoundinquadricepsfemoris comparedtotheabdominal
muscle. This could be due to higher physical activity
undertaken by the quadriceps femoris muscle and its higher
metabolic capabilities [31]. Thus, the increase in PPARγ
expression in the GA-treated rats suggests possible upregu-
lation by GA. Increase in PPARγ expression correlates with
enhanced insulin-stimulated glucose uptake into the muscles
mediated by increased insulin-stimulated P13K activity and
translocation of GLUT4 towards the cell membrane [32].
Thus, the signiﬁcant increase in total PPARγ expression of
the quadriceps femoris muscle in the GA-treated rats was
probably due to enhancement in insulin-stimulated glucose
uptake mechanisms. Wang et al. [33] have reported that a
lack of LPL expression in the skeletal muscle could result in
insulin resistance in other metabolic tissues (e.g., liver and
kidney). This could ultimately lead to obesity and systemic
insulin resistance.
The expressions of PPARγ and LPL in the kidneys are
lower compared to those of adipose tissue, complement-
ing the fact that the kidney is not the main regulatory
organ involved in lipid and glucose homeostasis [5]. The
upregulation of total PPARγ in the kidney in the present
study suggests the potential regulation of renal sodium and
water reabsorption [34]. Most importantly, the activation
of PPARγ also renders renoprotective eﬀects on the kidneys
through improved glucose metabolism [35].
Both the visceral and subcutaneous adipose tissues
displayed the highest expression levels of total PPARγ and
LPL compared to the control tissues, thus substantiating
their importance in adipogenesis and adipocyte remodeling.
Increased PPARγ expression levels in the liver and skeletal
muscles may indicate an increase in circulatory glucose
uptake by glucose transporters. The PPARγ expression levels
were the lowest in the kidney, which plays an important
role in the regulation of electrolyte concentration and
blood pressure. The upregulation of total PPARγ and LPL
expression levels coupled with a decrease in blood glucose
and serum insulin levels as well as HOMA-IR indicated
improvement in insulin sensitivity most likely due to ligand-
binding activation of PPARγ.
In conclusion, we have demonstrated that GA lowered
serum insulin, blood glucose and HOMA-IR signiﬁcantly
in rats compared to the control group. Improvements in
serum lipid parameters with a decrease in triacylglycerol,
total cholesterol and LDL-cholesterol and an elevation in
HDL-cholesterol were observed. All six tissues (liver, kidney,
abdominal and quadriceps femoris muscles, and visceral and
subcutaneous adipose tissue) examined displayed upregula-
tion of total PPARγ and LPL expression levels. Quadriceps
femoris and abdominal muscles and visceral adipose tissue
showed a signiﬁcant increase in total PPARγ and LPL
expression. Increase in expression levels of total PPARγ and
LPL in all the tissues was representative of their functions as
regulators of glucose homeostasis.
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